Immune checkpoint blockades (ICBs), including antibodies to PD-1, PD-L1 or CTLA-4, etc, may be effective in treating BCa (72), nevertheless, their response rates remain relatively low in unselected tumor patients (73–75). This evidence concerns the gene CD274 and neoplasm.